Story
Eurofins Scientific Reports Slow H1 Organic Growth, Beats Profit Estimates

Eurofins Scientific reported first-half organic growth that fell short of analyst expectations, citing persistent headwinds in its biopharma and diagnostics businesses. The laboratory testing group's second-quarter organic growth of approximately 3% also missed the consensus estimate of 4.2%, according to the company's latest financial release.
Key Financials Show Mixed Results
Despite the slower top-line growth, Eurofins delivered stronger-than-expected profitability. The company posted first-half revenue of €3.701 billion, which was in line with market consensus, even with a 2.9% headwind from foreign exchange rates.
Key performance indicators for the first half include:
- Adjusted EBITDA: Reached €877 million, 4% above the consensus estimate of €844 million.
- Adjusted EBITDA Margin: Improved by 130 basis points year-over-year to 23.7%, surpassing the forecast of 22.8%.
- Adjusted Earnings Per Share: Rose 25% year-over-year to €1.64.
- Free Cash Flow: Increased 46% year-over-year to €403 million after investments.
Biopharma Weakness Drags on Growth
AdThe company's biopharma segment experienced a sequential decline, contracting by 1.1% in the second quarter after growing 1.1% in the first. Eurofins noted that its contract development and manufacturing organization (CDMO) activity remained weak, while its product testing division was stable.
Geographically, growth in North America remained subdued at 2.0% in the second quarter. Europe saw a marginal improvement, with growth accelerating to 2.3% in the second quarter from 1.6% in the first. The company's net debt to EBITDA ratio held steady at 2.2 times, unchanged from the end of fiscal year 2025.
Outlook Reaffirmed
Eurofins maintained its full-year guidance, continuing to target mid-single-digit organic growth and an adjusted EBITDA margin above the fiscal year 2025 level of 22.5%. The company also expects year-over-year improvement in free cash flow.
Management cautioned that achieving these targets will "depend on the speed of pick-up of business in certain ancillary activities, and the end of contraction in others."
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.